Heather Graham, APRN
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,927 of the $6,312 with a category attached, or 78.1%. 21 manufacturers reported payments, led by Medtronic at 34.8% of the total. 2025 is the largest year on record at $2,742, more than ten times the $187 reported in 2021. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Averitas Pharma Inc.$1K
- Abbott$575
- AbbVie$358
- Scilex Pharmaceuticals Inc.$351
- Pfizer$270
- plus $1K from 15 others
What the payments were for
- Travel & lodging$1,33921%
- Food & beverage$4,92778%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 49 | $2,195 |
| Averitas Pharma Inc. | 56 | $1,100 |
| Abbott | 34 | $575 |
| AbbVie(2 entities) | 17 | $358 |
| Scilex Pharmaceuticals Inc. | 20 | $351 |
| Pfizer | 26 | $270 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $216 |
| Collegium Pharmaceutical, Inc. | 9 | $166 |
| IBSA Pharma Inc. | 7 | $164 |
| Amgen(2 entities) | 14 | $160 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $140 |
| Nevro Corp. | 3 | $130 |
| CSL Behring | 4 | $114 |
| GRT US Holding, Inc. | 7 | $103 |
| Boston Scientific | 4 | $88 |
| Merz Pharmaceuticals, LLC | 2 | $60 |
| Globus Medical | 1 | $31 |
| Fidia Pharma USA Inc. | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Nalu Medical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$1,264
- Omnia$109
How this compares
$6,312 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 140 | $100,543 |
| MovantikNaloxegol Oxalate | 81 | $30,807 |
| OxycontinOxycodone Hcl | 60 | $28,690 |
| Nurtec OdtRimegepant Sulfate | 14 | $26,441 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 787 | $25,865 |
| BelbucaBuprenorphine Hcl | 29 | $21,023 |
| Diclofenac Sodium | 472 | $20,540 |
| Lidocaine | 122 | $14,750 |
| Gabapentin | 702 | $14,440 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 502 | $12,015 |
| Tramadol Hcl ErTramadol Hcl | 173 | $10,363 |
| ZtlidoLidocaine | 13 | $8,994 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,142 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,062 |
| Methocarbamol | 251 | $5,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $166 | $121,566169 claims |
| PfizerNurtec Odt | $270 | $26,44114 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $351 | $8,99413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Dover
- Shannon CullinDover$5K
- Amanda BooneDover$5K
- Tina VarugheseDover$3K
- Patricia PowellDover$3K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.